Canagliflozin's CREDENCE trial showed the strongest kidney-specific evidence for any SGLT2 inhibitor at the time of publication, with a 34% reduction in end-stage kidney disease alone (HR 0.68, P=0.002) [11]
My order arrived safely, and everything inside was well protected
People with a history of disordered eating, particularly restrictive eating disorders such as anorexia or orthorexia, should be cautious about both semaglutide-driven appetite suppression and the rigid food rules inherent in ketogenic eating
There's something deeply reassuring about knowing you can see specialists without referrals and that your coverage travels with you from Durango to Denver to Delaware
Cold sensitivity isn't typically a reason to switch formulations, since the active medication is the same
The UK GLP-1 programme appears to offer a more limited support model focused on workshops, community, and app-based content rather than 1-to-1 clinical coaching